|1.||Sumiyoshi, Tomiki: 7 articles (01/2014 - 06/2006)|
|2.||Meltzer, H Y: 5 articles (06/2013 - 06/2000)|
|3.||Hamada, Takeshi: 5 articles (12/2010 - 04/2002)|
|4.||Takei, Asako: 5 articles (12/2010 - 04/2002)|
|5.||Tashiro, Kunio: 4 articles (12/2010 - 04/2002)|
|6.||Uehara, Takashi: 3 articles (01/2014 - 06/2006)|
|7.||Meltzer, Herbert Y: 3 articles (07/2013 - 05/2007)|
|8.||Higuchi, Yuko: 3 articles (01/2013 - 05/2007)|
|9.||Yabe, Ichiro: 3 articles (01/2005 - 04/2002)|
|10.||Fukazawa, Toshiyuki: 3 articles (01/2004 - 04/2002)|
02/01/2002 - "Diverse effect of tandospirone may be caused by its partial agonist activity on 5-HT1A receptors, or may indicate that other causes for the expression of dyskinesia exist apart from excessive rise in brain DA levels. "
02/01/2002 - "Twelve weeks after tandospirone treatment, duration of dyskinesia, subjective and objective severity of dyskinesia, and parkinsonian features were evaluated. "
02/01/2002 - "The present study demonstrated that tandospirone is effective in alleviating L-DOPA-induced dyskinesia in 50% of the patients. "
02/01/2002 - "Tandospirone(15-60 mg/day) was administered to 10 patients with L-DOPA-induced peak-dose dyskinesia. "
07/01/2003 - "Drugs with 5HT-(1A) agonistic activity, such as buspirone and tandospirone, have been reported to be effective in reducing l-dopa-induced dyskinesias. "
|2.||Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome)
11/01/2000 - "We reported a 64-year-old woman in the early stage of progressive supranuclear palsy presenting as pure akinesia syndrome who showed marked improvement with tandospirone citrate. "
02/01/2001 - "[A case of progressive supranuclear palsy improved with tandospirone citrate]."
01/01/2002 - "[Clinical effectiveness of tandospirone citrate (5-HT1A agonist) on patients with progressive supranuclear palsy]."
11/01/2000 - "[Effects of tandospirone citrate on frozen gait in patients with early stage of progressive supranuclear palsy, investigated by walk-induced activation single photon emission computed tomography method]."
02/01/2001 - "We reported a 74-year-old male case of progressive supranuclear palsy (PSP) who responded to tandospirone citrate, a serotonin receptor (5-HT1A) agonist. "
|3.||Postoperative Nausea and Vomiting (PONV)
11/01/2002 - "We have hypothesized that the 5-hydroxytrypta-mine-1A receptor agonist tandospirone reduces postoperative nausea and vomiting (PONV). "
11/01/2002 - "Oral tandospirone reduced the incidence of postoperative nausea and vomiting without significant adverse effects in adults undergoing tympanoplasty under general anesthesia."
11/01/2002 - "In conclusion, premedication with oral tandospirone is effective against PONV in patients undergoing tympanoplasty under general anesthesia. "
09/01/2008 - "The available nontraditional antiemetics that have been shown to be effective for the prophylaxis against PONV are propofol, dexamethasone, tandospirone, and midazolam. "
|4.||Schizophrenia (Dementia Praecox)
12/01/2010 - "Effect of tandospirone on mismatch negativity and cognitive performance in schizophrenia: a case report."
10/01/2001 - "Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment."
06/01/2000 - "Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia."
01/01/2015 - "Previous pilot clinical studies have shown that the serotonin 5-HT1A receptor agonist tandospirone has beneficial effect on cognitive deficits associated with schizophrenia. "
01/01/2014 - "The purposes of this study were to examine the effect of repeated administration (once a daily for 4 days) of tandospirone (0.05 or 5 mg/kg) on brain energy metabolism, as represented by extracellular lactate concentration (eLAC) in the medial prefrontal cortex (mPFC) of a rat model of schizophrenia. "
11/01/2009 - "Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial."
06/01/2005 - "Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia."
06/01/2005 - "Sixty-four functional dyspepsia patients without Helicobacter pylori infection were randomly assigned to 15 mg/day of mosapride, 40 mg/day of famotidine, or 30 mg/day of tandospirone during an 8-week treatment. "
01/01/2008 - "Mosapride was as effective as famotidine and itopride, but more effective than tandospirone, in improving overall or individual symptoms of functional dyspepsia in randomized trials. "
|1.||Serotonin 5-HT1 Receptor Agonists
|2.||Citric Acid (Citrate)
|3.||Levodopa (L Dopa)
|7.||D-Aspartic Acid (D Aspartate)